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PRION PROTEIN AS AN INFECTIOUS AGENT OF TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES
WIOLETA CYRANEK
ABSTRACT

Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases
of human, animal and yeast caused by an infectious agent designated prion. The
"protein only" hypothesis proposed more than three decades ago suggests that the
prions are small, infectious pathogens composed of aggregated, abnormal forms of a
protein encoded in the host genome. PrPC plays primary role in neurite outgrowth,
synaptic function, oxidative stress defense and long term survival of cerebellar neurons.
The key event in prion disease is the conversion of the α-helical, cellular isoform of the
prion protein to the insoluble, β-sheet-rich disease- causing isoform. Aggregation of
misfolded prion protein into large amyloid plaques and fibrous structures is associated
with neurodegeneration. TSEs attack the central nervous system leading to progressive
spongiform degeneration of brain tissue. Molecular and cellular pathways leading to
neurodegeneration remains still unclear. However, the recent studies suggest that
pathway leading to neuronal loss include ubiquitin-proteosome and endosomal system,
oxidative stress, regulated activation of complement, synaptic alterations and dendritic
atrophy. The study of the unusual properties of the infectious agent and pathology of
neurodegenerative disorders has been a source of excitement and arguments between

the scientists. The major advances in molecular genetics and recent understanding of
prion propagation and neurotoxicity allowed deep insight into prion biology.
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CHAPTER I
INTRODUCTION

Proteins are the most versatile molecules in the cell. They play an important role
in all biological processes. Protein function is assured by its synthesis inside the cell
followed by folding into the specific conformational state that is encoded in its
sequence. The ability of proteins to fold to their functional states is one of the most
remarkable features of biology. However, under some conditions, proteins fail to fold
correctly or to remain correctly folded, in living system, and this failure can result in a
wide range of disorders. The accumulation of misfolded proteins is a common feature of
several neurodegenerative diseases associated with the deposition of proteinaceous
aggregates in a variety of organs such as liver, heart and brain. The proteins involved in
these conditions are known as prions (proteinaceous infectious particles).1 Intracellular
accumulation of cellular form of prion protein might significantly impair cell function
and lead to cytopathology.

2

Prion diseases belong to a group of conformational

disorders affecting the central nervous system of multiple species. The pathological

1

mechanism relies upon conversion of physiological cellular proteins into insoluble and
toxic conformers accumulating in the brain during the course of the disease. The
conversion of largely α-helical proteins into cross-β-plated sheet conformations
underlies these disorders.

3,4

Prions are associated with a group of diseases called

transmissible spongiform encephalopathies (TSEs). Those include Creutzfeldt-Jacob
disease (CJD), kuru, fatal familial insomnia (FFI), Gerstman-Straussler-Scheinker
disease(GSS)

in humans, scrapie in sheep, goats, mouflons, transmissible

encephalopathy (TME) in mink, bovine spongiform encephalopathy (BSE) in antelopes,
feline

spongiform

encephalopathy

(FSE)

in

domestic

cats,

exotic

ungulate

encephalopathy (EUC) in nyala and greater kudu, and chronic wasting disease (CWD) of
mule deer and elk. 5

2

CHAPTER II
PRIONS
Prions are small, infectious pathogens composed of aggregated, abnormal forms
of a protein encoded in the host genome. The protein adopts two forms: normal and
infectious. To date, no detectable nucleic acid and no virus-like particles have been
associated with prions. 6,7
2.1. Discovery

The unusual properties of the infectious agent became the focus of attention
beginning in the 1960s. Gibbon, Hunter, Griffith and Levine observed that the agent
causing scrapie and Creutzfeldt-Jacob disease is resistant to ultraviolet radiation and
consists solely of proteins. In the late 1970s and early 1980s other researchers found
that scrapie agent was insensitive to proteolitic digestion.

8

In 1982, Stanley Prusiner

and coworkers first isolated and characterized a putative infectious agent from the

3

scrapie-tainted brain tissue and proposed the ”prion only hypothesis”. This model
postulated

that

the

pathogenic

agent

causing

transmissible

spongiform

encephalopathies in human and animal, consists mainly or entirely of PrPSc, a
conformational variant of the constitutively expressed host glycoprotein PrP C without
any encoding nucleic acid. The information for prions is enciphered in the structure of
the pathological isoform. 6, 7 The isolation and investigation of the Prnp gene expression
in 1985 showed that prion protein was present not only in infected animals, but also in
healthy animals.

9

Moreover, in the absence of cellular expression of PrPC, even when

nonneuronal tissue contains dense deposit of PrPSc neuronal death does not occur.

10

Conformational change of the cellular form of prion protein to a pathological, disease
associated form is considered central to pathogenesis and formation of the infectious
agent or prion.

11, 12

The conformational change of PrPC into PrPSc results in a

fundamental change of its biophysical properties. 4
Although PrPSc is the only known component of the prion particle, these
pathogens share some phenotypic traits with viruses. Therefore, some scientists reject
the prion protein hypothesis and propose other theories .The most popular is the virino
hypothesis which postulates that scrapie agents are a molecular chimera composed of
host encoded shell-protein and a nucleic acid.

5, 13

However, several main features

distinguish prions from viruses. First, there is no evidence for nucleic acid within a prion
particle, whereas viruses are composed of a nucleic acid genome which serves as the
template for the synthesis of progeny virus. Second, PrPSc encoded by a chromosomal
gene, is the only known component of the prion, whereas viruses are composed of
4

nucleic acid, proteins and often other constituents. Third, viruses exist in a single form
with distinct ultrastructural morphology; prions can exist in multiple molecular forms.
Fourth, prions are non-immunogenic in contrast to viruses.

7, 13

Moreover, prions

encipher strain-specific properties in the tertiary structure of PrPSc in contrast to
pathogens with nucleic acid that encode these properties in genes.

14

The data from

numerous studies presents evidence against the virino hypothesis.
The “unified theory” proposed by Weissmann suggests that the infectious agent
designated apoprion is a molecular chimera composed of the misfolded protein that
confers infectivity, and unidentified oligonucleotide that specifies strain characteristics.
5, 15

According to this model apoprion can mediate the infectious process independently

or together with the small nucleic acid within the host, the co-prion. 5
Accumulated evidence supports the protein-only model of infection. The main
evidence is the absence of nucleic acid and the resistance of prion to reagents that can
damage or modify genetic material (DNAse, RNAse) and susceptibility of infectivity to
agents which destroy protein (trypsin, proteinase K).

7

Additional evidence for the

protein-only model comes from yeast and fungi. 16 Two yeast proteins Ure2p and Sup35
after conformational change can form infectious isoforms ([URE3] and [PSI+] in
Saccharomyces cerevisiae). 17

5

CHAPTER III
CELL BIOLOGY OF PrP ISOFORM
3.1. PrPC
PrPC is normal cellular isoform of the protein. It is expressed in the neurons, glia
of the brain and spinal cord, in several peripheral tissues and in leukocytes. In the adult
central nervous system, PrPC and its mRNA are widely distributed, with particular
concentration in hippocampal and neocortical neurons, cerebellar Purkinje cells, and
spinal motor neurons.

18

However, the highest levels of expression are seen in the

central nervous system in association with synaptic membranes. PrPC is expressed
during early embryogenesis. 19
3.1.1. Processing
PrPC is a highly conserved cell membrane sialoglycoprotein. It is encoded by cellular
gene located on chromosome 20 in man (PRNP) and chromosome 2 in mouse (prnp).
(Figure 1) Human PRNP gene consists of 2 exons (3 exons in mice, cattle, and some
6

other species) and an open reading frame located within exon 2 (or 3 in species contain
3 exons).8
Figure 1. PrP processing. Normal form of protein PrPC is synthesized from mRNA within
the cell and processed on its way to the cell surface. Two glycans (CHO) at position 181
and 197 are added during the maturation process. Carboxy-terminus and leader
sequence are removed before sending to the cell surface. Membrane anchor (GPI
anchor) is covalently attached to protein. PrPC is converted into a pathological isoform.
Proteolitic cleavage of PrPC with proteinase K yield 17 kDa N-terminally truncated form
C1. PrPC is completely degraded. Digestion of PrPSc yields a peptide designated C2 and a
“core protein” designated PrP27-30 8.
The human PrPC protein is synthesized as a 253 amino acid polypeptide chain.
The first 22 amino acids (signal peptide) are cleaved shortly after translation. During
maturation PrPC undergoes several kinds’ of posttranslational modification including
addition of N-linked oligosaccharide chains at two sites, formation of a single disulfide
bond, and attachment of the GPI anchor at residue 230, which facilitates glycolipid

7

linkage of PrPC to the cell membrane.

20

Lack of GPI anchor decrease the infectivity of

prions and leads to less neurodegeneration.

11, 21

PrPC is the final product which is

converted into infectious isoform. PrPC is expressed equally in the cells of both normal
and infected animals.
3.1.2. Structure

PrPC is usually monomeric in structure, protease sensitive, and linked to cellular
membranes through a glycophosphatidylinositol (GPI) anchor. It is a four-helix bundle
protein containing four regions of secondary structure denoted H1 through H4.

20

PrPC

contains about 40 % α helix and little anti-parallel β sheet. (Figure 2) Both N–terminal
and C-terminal region of the natural protein consist of around 100 amino acid. 22 The Cterminal domain is composed largely of α-helical structure (with three α-helices and a
short anti-parallel β-sheet) stabilized by a single disulphide bond linking helices 2 and 3.
22

The N-terminal region is very highly conserved in evolution. It contains the

octapeptide repeat region between residues 51 and 91 (five repeats of an 8 amino acid
sequence)with two tight binding sites for Cu(II) ions and neural cell adhesion molecule
(NCAM) that interacts with PrPC at the neuronal cell surface. Binding of PrPC protein to
Cu(II) ions may regulate cellular copper homeostasis under oxidative conditions.
Interaction of PrPC with NCAM at the neuronal surface may promote recruitment of
NCAM to lipid rafts and thereby regulate activation of fyn kinase, an enzyme involved in
NCAM-mediated signaling.

23

Mutations in the octapeptide repeat region, resulting in

8

addition of integral numbers of additional repeats, leads to forms of inherited prion
disease.24

Figure 2. Structure of PrPC and PrPSc.
http://universe-review.ca/F11-monocell.htm

The prion protein exists in three different topologies: a secreted form (SEC)
attached to the outer of the lipid bilayers by a C-terminal GPI, a transmembrane form
that spans the lipid bilayer in which the C-terminus is extracellular (CTM), and a
transmembrane form in which the amino terminus is extracellular (NTM).The sequence
encoding residues 151-165 that forms transmembrane region is highly conserved. 25 The
transmembrane forms are pro-apoptotic and associated in neurodegeneration in vivo,
whereas the secreted form is anti-apoptotic. Many studies suggest that CtmPrP is a main
pathogenic form associated with neurodegeneration.26

9

3.1.3. Function

Although the normal biological function of PrP C is still unknown, PrPC is
implicated in diverse activities. Possible functions include: neuronal neurite outgrowth
and synapse formation, differentiation of neural stem cell, interaction with signal
transduction pathway, neuritogenesis, neuronal survival via pro- or anti-apoptotic
functions, synaptogenesis, long-term memory formation, development and activation of
T cells, modulation of phagocytosis of leukocytes , and altering leukocytes recruitment
to the sites of inflammation. 27, 28, 29 Knockout experiments suggest expression of PrP is
not crucial to the survival of organism. 30
3.1.4. Cellular trafficking

PrPC protein is synthesized first in the endoplasmatic reticulum, matured in the
Golgi apparatus, and carried in its mature form to the cell surface usually anchored by
GPI moiety.

31

(Figure 3) Generation of PrPSc occurs after arrival of PrPC at the cell

surface. PrPC at the surface is predominantly located in specialized detergent-resistant
microdomains (DRM) known as lipid rafts. PrPC may be internalized and processed
through the endosomal-lysosomal system, which may also be substrate for their
interaction. 8, 31 PrPC can be subjected to endocytosis and either recycled to the plasma
membrane via recycling endosomes or degraded in lysosomes. PrPC may also be
transported through the membrane as multivesicular-bodies derived exosomes. 32 Small
membranous particles can be released from multivesicular bodies and fuse with the

10

membranes of other cells, providing a potential mechanism for the spread of infectivity
between cells. 27

Figure 3. Subcellular localization and trafficking of PrPC. a) PrP anchored to plasma
membrane. b). Cellular trafficking of PrP. c). Neuronal cell with fluorescently tagged
PrPSc. 27
http://proxy.ulib.csuohio.edu:2319/nature/journal/v443/n7113/box/nature05294_BX1.html

In central and peripheral nervous system neurons, fast anterograde and
retrograde axonal transport of PrPC facilitating movement to and from neural
extremities have also been detected. 2, 8 Up to 10% of newly synthesized protein might
be retrogradely transported from the endoplasmic reticulum to the cytosol, where it
undergoes degradation.

11

3.2. PrPSc

The "Sc" superscript is used to designate the scrapie-like isoform of PrP since all
of the known prion diseases of mammals involve aberrant metabolism of PrP similar to
that observed in scrapie. PrPSc is derived from PrPC by a post-translational mechanism
and no covalent differences between both forms have been demonstrated. PrP Sc acts as
a template which promotes the conversion of cellular form. The difference between
PrPSc and PrPC lies in their conformation and the state of aggregation.

22

The same

primary amino acid sequence of PrPSc corresponds to that encoded by the PrP gene but
its secondary structure is dominated by beta conformation. PrPSc is composed of about
30% α helix and 45% β sheet.

33

(Figure 2) Enhanced β sheet content accounts for its

innate amyloidogenicity with strong tendency to self-aggregation and fibril formation.
Infectious forms of PrP vary and are poorly defined structurally, but are most commonly
multimeric (aggregated) and more protease-resistant than PrPC.

34

PrPSc is able to

replicate and propagate itself by transferring its altered conformation to the
endogenous PrPC, a cell surface-enriched protein that becomes partially resistant to
proteases and accumulates in plaques in the brain. PrPSc is partially hydrolyzed by
proteases to form an infectious fragment designated PrP27-30, while PrPC is completely
degraded under the same condition. Proteinase K digestion of PrPSc removes a variable
number of N-terminal aminoacids (up to around residue 90). N-terminus can be cleaved
anywhere from residue 74 to 102. However, a protease sensitive disease associated
transitional form has also been described. 35

12

The protease resistant central core of PrPC designated PrP27-30 was first
discovered as a protein copurifying with scrapie infectivity. It was found in the amyloid
plaques in brains from humans and animals with putative prion diseases (GSS, vCJD
patients and some kuru patients). This form was absent in other disorder such as
Parkinson or Alzheimer’s disease. 5 The core protein ranges in size from 27 to 30 kDA. Its
tertiary structure is probably distinct from the tertiary structure of normal protein. It
doesn’t have GPI anchor, cysteine bond and glycosylation sites. It polymerizes into rodshaped structures with high content of B sheet which are indistinguishable structurally
from many purified amyloids.36
Infectious isoform is also resistant to heat, radiation, and formalin treatment commonly
used to destroy viruses and other pathogens.

23

PrPSc accumulates, whereas PrPC turns

over rapidly. The patterns of PrPSc accumulation in brain are distinct from the
distribution of PrPC. 36
PrPSc accumulate in amygdale, especially in the medial habenular nucleus, the medial
septal nuclei, and the diagonal band of Broca. 33

13

CHAPTER IV
CONVERSION OF PrPC INTO PrPSc

Conversion of PrPC into PrPSc is the central event in the pathogenesis of transmissible
prion diseases.

11

Conversion of PrPC into PrPSc is conformational rather than covalent.

Two isoform are chemically indistinguishable, have the same primary amino acid
sequence and probably the same posttranslational additions. The main difference
between PrPC and PrPSc seems to be conformational, with PrPSc having a higher B–sheet
content and being multimeric.

5

PrPSc is derived from PrPC by a post-translational

modifications. Isoform PrPSc acts as a template that promotes the conversion of PrPC to
PrPSc. Specific direct binding between PrPC and PrPSc precedes the conversion of PrPC to
the PrPSc conformation.

20

The molecular mechanism of that process is still unknown.

The experimental data suggest that the conformational alteration could be induced by a
yet unidentified event, which occurs spontaneously or by contact with external prions,
or by awakening of silent prions. 2 There are two proposed competing mechanisms of

14

conversion PrPC to PrPSc. (Figure 4) The refolding model was originally proposed by
Griffith and expanded by Pruisner. It suggests that interaction between externally
introduced PrPSc and cellular PrPC and mixing of those monomers leads to the formation
of PrPC - PrPSc heterodimer which in turn rapidly converts to PrPSc homodimer.

The seeding mechanism was proposed by Griffith and expanded by Gajdusek and
Lansbury. It suggests that the normal and infectious forms of the prion protein are in
equilibrium. PrPSc oligomer or polymer acts as a "bad seed." It can recruit more PrPSc,
increase replication of the infectious agent and eventually aggregate to form amyloid.

Figure 4. Two model of conversion of PrPC into PrPSc.
www.nature.com/.../v4/n9/fig_tab/nri1437_F1.htm

15

In the infectious manifestation of prion disease, extracellular PrP Sc interacts with
PrPC in lipid rafts on the plasma membrane or in the endocytic organelles, catalyzing its
conversion to PrPSc. Once formed, PrPSc is metabolically stable and accumulates in
intracellular organelles, perhaps endosomes and lysosomes, which may be the site
where the N-terminus of the protein is proteolitically cleaved. In familial prion disorders,
conversion to PrPSc is induced by a mutation in the amino acid sequence of the protein.
Mutant PrPC is converted spontaneously via a series of biochemical intermediates, the
earliest of which is a PI-PLC–resistant form generated in the ER and delivered to the cell
surface.

18

Although, at least 15 PRNP polymorphisms are known, only methionine or

valine at codon 129 is clearly influential in all disease form. 2

16

CHAPTER V
PRION STRAINS

One of the many remarkable features of prions is the existence of distinct
strains. They share the same PrP sequence (identical primary structure) but lead to
distinct disease-associated pathology in the brain. These pathological changes include
gliosis, spongiosis, neuronal vacuolation, and diffuse versus plaque-like PrP deposits.
Approximately 20 strains of scrapie agent have been isolated from sheep and goats
affected with clinical scrapie. 5 The same strain can be isolated from different hosts and
the same host can be infected with different strains. Strains of prions have been defined
by incubation times and the distribution of neuronal vacuolation.

37

Several main

features distinguish prions strains. Distinct strains are distinguished by their physical and
chemical differences, and by differences in biological properties on transmission to
laboratory animals.

38

Multiple TSE strains have different incubation time and lesion

17

profiles upon serial transmission in congenic hosts. Different prion strains target distinct
cells in the brain and are localized in different cellular compartments. Distinct strains
induce morphologically diverse aggregates ranging from small deposits to large amyloid
plaques.

39

All this species-specific change in the PrPSc molecule is accompanied by an

alteration in the pathogenicity of the prion.

40

The existence of biologically different

strains of scrapie agent is still the strongest argument against the protein-only nature of
the scrapie agent. However, the recent studies suggested that the properties
manifested by prion strains such as incubation times and neuropathology profiles are
encoded by different conformation of PrPSc and glycosylation patterns.

41

Such PrP

interactions may be most efficient if the interacting proteins are not only of the same
sequence but have similar conformational preferences and glycosylation. The
experimental data provided by study of transmission of two different inherited human
prion diseases to mice expressing a chimeric MHU2M PrP transgene demonstrate that
strain-specific information is enciphered in the tertiary structure of PrPSc.

42

These

strains can be distinguished by differing physiochemical properties of the accumulated
PrPSc in the brains. Variations in tertiary structure of PrP Sc probably correlate with
differing surface exposures of the protein, and account for differences in cleavage sites
with protease digestion.

43

The difference in molecular size of two fragments (HY, DY)

after protease treatment was shown to be due to different sites of proteolitic cleavage
at the NH2 termini reflecting different tertiary structures.

20

Moreover, the existence of

variant CJD associated with PrPSc glycoform ratios distinct from those seen in classical
CJD strongly support the protein-only hypothesis and suggest that strain variation is
18

encoded by combination of PrP conformation and glycosylation. Only a limited number
of different PrPSc conformations that are highly stable will be permissible
thermodynamically and will constitute the range of prion strains seen. Different prion
strains can profoundly affect susceptibility of a particular species to prions from another
species. 7

19

CHAPTER VI
SPECIES BARRIER

Transmission of prion diseases between different mammalian species is
restricted by a “species barrier”. Transmission of prions from one species to another is
generally inhibited when compared to subsequent passage in the same host species.
The strain of prion, the difference in PrP sequence between the prion donor and
recipient and the species specificity of unknown factor that binds to PrPC and facilitates
PrPSc formation, contribute to the species barrier. 20
Prion diseases can be transmitted between species by dietary exposure (eating
of food contaminated with prion protein) or inoculation.

2

Iatronic routes include the

use of inadequately sterilized surgical and medical equipment because prions resist
conversional sterilization. In humans, transmission of the vCJD agent via blood
transfusion has been reported.
intravenous,

intracerebral

44

or

The disease can be transmitted experimentally by
intraperitoneal

inoculation.

experimentally with prion diseases are not contagious to humans.2

20

Animals

infected

CHAPTER VII
PRIONS DISESASES

Transmissible spongiform encephalopathies (TSEs) or prion diseases are
multifaced degenerative disorders in humans and
spontaneously, genetically or by infection.

5

animals.

They originate

The term spongiform refers to the

characteristic sponge shape lesions that are found in the brain of infected individuals.
The key event in prion disease is the conversion of the α-helical, cellular isoform of the
prion protein to the insoluble, β-sheet-rich disease-causing isoform.

3, 4

TSEs attack the

central nervous system leading to progressive spongiform degeneration of brain tissue.
The main clinical features include consequent dementia, motor dysfunction, paralysis
and mortality. All recognized prion diseases are invariably fatal. Neither humoral nor
cellular immunological responses have been detected in response to prion diseases
because PrPSc is very similar to host protein.

45

Although there are many morphologic

and pathophysiologic similarities between TSEs and other progressive encephalopathies,

21

such as Alzheimer and Parkinson disease, they are unique in that they are transmissible
by inoculation or ingestion of prion-contaminated material.
7.1. Spreading of disease

In most TSEs, infectivity and disease associated, the conformationally altered
form of PrP first accumulates in the lymphoreticular and secretory organs. Prion
transport and replication require follicle associated epithelium, M cells, follicular
dendritic cells, tangible and dome body macrophages. Supporting role have B cells and
complement system. Within days after oral exposure prions may penetrate the
intestinal mucosa probably through microfold cell and Peyer’s patches. Infectivity
appears in the spleen mainly in follicular dendritic cells and lymph nodes. Infectivity is
associated with B- and T-lymphocytes and with the FDC containing stromal fraction. 46,
47

Although FDC are the site of prion propagation in the spleen, some evidence such as

neuroinvasion without FDCs suggest the existence of other peripheral cells that can
replicate the prion.

48

Tissues of the lymphoreticular system are sites in which prions

accumulate and replicate. A significant role is played by gut–associated lymphoid tissue
and draining lymph nodes.

49

Myeloid dendritic cells mediate transport within

lymphoreticular system. However, Infections then spread to the peripheral nervous
system, leading eventually to neurodegeneration, accompanied by widespread
accumulation of PrPSc. Prions are transported to the brain primarily by peripheral
nerves. Prion diseases affect different parts of the brain. The main parts include cerebral
cortex, thalamus, cerebellum and brain stem. (Figure 5)

22

Figure 5. Regions of the brain affected by prions.
http//nobelprize.org/.../1997/illpres/brain.html

Morphological analysis shows that first, neurons develop small, round or oval (≤
10 µm) intracytoplasmic vacuoles. With continuous vacuolization, cortical neutrophils
develop a spongy looking form. Spongy degeneration especially in the second cortical
layer is commonly seen in various neurodegenerative diseases.

2,

50

PrPSc can also

accumulate in astrocytes and microglia. Infection can next disseminate within the
central nervous system and spread eventually to peripheral sites such as muscle. 51 The
vagus and splanchic nerves are paths for the initial spread to ganglia and to the CNS.
Infection of muscle may happen via neural pathways, for example, efferent projection of
motor units to neuromuscular junction and postsynaptically into muscle fibers.
Infectivity has been found in some skeletal muscle of mice experimentally infected with

23

ME7 or RML prions, although prions have not been detected in muscle of BSE-infected
animals and scrapie. 52
7.2. Type of prion diseases

Prion diseases are divided etiologically into inherited, acquired (iatrogenic) and
sporadic forms.
10-15% of recognized prion disease is an inherited disorder associated with
coding mutations in PRNP gene. More than 30 mutations of the PrP gene have been
identified in families suffering from inherited human prion diseases. Researchers
suggest that the mutations in the PrP gene lead to production of unstable PrP C protein
that can spontaneously convert into the abnormal isoform.

53

Pathogenic mutation

includes point and insertional mutation. Point mutations occur in the C-terminal domain
of PrP and lead to aminoacid substitution. Insertional mutation encoding additional
integral copies of an octapeptide repeat that is present in five copies in the normal
protein occur in the N–terminal domain of the PrPC. Not all PRNP mutation-associated
disease in humans is transmitted. The inherited prion diseases can be further subdivided
into 3 phenotypes: fCJD, GSS, FFI. 20
The acquired prion diseases include CJD, variant CJD, BSE, scrapie and kuru.
Infections arise from accidental exposure to human prions through participation in
cannibalistic feasts or medical procedures (i.e. treatment with pituitary derived
hormones, tissue grafting, corneal transplantation, and neurosurgery). 54

24

Sporadic form is the most common and makes up around 85% of all diagnosed
human prion disease. CJD and FFI occasionally occur in people who have no family
history of the disease and no known exposure to infectious prions. The possible causes
are: spontaneous somatic mutation of PRNP, spontaneous transition of PrPC into PrPSc
or unidentified environmental prion exposure. The sporadic CJD occurs in homozygote
at codon 129 encoding valine or methionine. Heterozygotes do not develop this disease.
Polymorphism of PRNP at codon 129 which is a major determinant of genetic
susceptibility to and phenotypic expression of prion disease is associated with four
different types of human infectious protein. PrPSc type 1 and 4 is observed in MM
individuals, type 3 in MV or VV and is predominantly associated with at least one V
allele. Type 2 has been detected in any PRNP codon 129 genotype. PrPSc type 1-3 is
associated with sporadic, iatrogenic and classical CJD. Type 4 human PrP Sc is
predominantly associated with vCJD. 55
7.3. Protein aggregation and disease
PrPC and its pathological isoform bind to each other forming aggregates. It is still
not clear if these aggregates are the cause of the cell degeneration or a side effect of
disease. There are a few hypotheses that developed during the past 15 years to explain
the relationship between protein aggregation and disease. The first hypothesis states
that the formation of aggregates is a direct effect of disease. Conversely, the “amyloid
model” states that human neurodegenerative disorder causes fibrillar- protein
deposition.

34

However, there are many evidences that argue against both hypotheses.
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Amyloid plaques were found in the brain of normal 70 years old individuals. Protein
aggregates are not always coupled to disease and some disorder such as GSS do not
show fibrillar deposits of abnormal protein. Moreover, the amount and the size of
amyloid plaques examined in postmortem brain do not correlate with severity of
symptoms at the time of death
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. Therefore, researchers proposed the third revised

model to explain the qualitative correlation (protein deposition are not quantitatively
correlated with disease) between the disorder and protein aggregation. This hypothesis
states that unknown agent initiates both protein aggregation and the disease. This
model explains extreme situation described above and suggests the existence of
“prevalent deposits but little or no disease or conversely severe disease with little or no
deposits”. 34
7.4. Mechanism of cell death

Death of the nerve cell underlies the clinical symptoms of prion diseases.

8

However, the cellular pathways and the molecular mechanism that cause the neuronal
damage are still not entirely clear. Early studies argued that the neuronal damage might
be the effect of loss of the normal function of PrPC or gain of toxic property of PrPSc. 2
In the absence of normal form of protein neuronal loss does not occur. The
disease is prevented when neurons cannot produce normal form of protein even in the
presence of dense deposits of abnormal isoform. 56 Moreover, early neuronal damage is
reversed when neuronal PrPC is depleted in mice with ongoing prion infection. 57 Hence,
conversion of normal protein to infectious isoform is central to pathogenesis.
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Therefore, the main question is whether PrPSc is itself directly the cause of the
neuronal damage. In vitro experiments show that PrPSc and short PrP peptides are
neurotoxic. However, prion diseases occur with high levels of PrPSc in brain with or
without clinical symptoms. There are examples of prion infection in which the level of
pathological isoform is very low or even not detectable. 58According to the latest studies
prions themselves are not directly neurotoxic. Toxic species derived during prion
propagation produced directly from PrPC or as a PrPSc precursor, are probably
responsible for neuronal damage. 27
Molecular and cellular pathways leading to neurodegeneration remains still
unclear. However, recent studies suggest that the pathway leading to neuronal loss
include ubiquitin-proteosome and endosomal system, oxidative stress, regulated
activation of complement, synaptic alterations and dendritic atrophy. 2 (Figure 6)

Figure 6. Pathogenic events in prion disease. http://ajp.amjpathol.org/cgi/contentnw/full/172/3/555/F3
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7.5. Human prion diseases

Human prion disease has been classified into: Creutzfeldt-Jacob disease (CJD),
kuru, fatal familial insomnia (FFI), Gerstman-Straussler-Scheinker disease (GSS) and
Alpers’ disease.

5

Prion protein causes characteristic lesions in the brain with

characteristic spongiform vacuolation, accumulation of amyloid plaques, neuronal cell
loss, microglial activation and proliferation of astrocytes. Neuropathologically, these
disorders produce a characteristic spongiform degeneration of the brain, as well as
deposition of amyloid plaques.
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The primary symptom of the human disorders is

dementia, usually accompanied by manifestation of motor dysfunction such as
cerebellar ataxia, myoclonus, pyramidal or extrapyramidal signs. 18
7.5.1. Creutzfeldt-Jacob disease (CJD)

Creutzfeldt-Jacob disease was discovered by two physicians, Creutzfeldt and
Jacob in the 1920s. There are three different forms of CJD: sporadic, inherited and
iatrogenic. 22
Sporadic (classical) CJD is a rapidly progressive, multifocal dementia, with two or
more myoclonus that affects individuals between 45-75 years. Around 90% of patients
die within 12 months. The central clinical feature include: mental deterioration,
insomnia, depression, general malaise, fatigue. Damage to the cerebral cortex
associated mainly with CJD results in loss of memory and very often visual impairment.
Cognitive decline and behavioral disturbance are invariable features.
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54, 56

Myoclonus

and cerebellar ataxia are recognized in up to 70–80% of cases. Frequent additional
neurological features compromise: cortical blindness, pyramidal, extrapyramidal and
cerebellar signs, akinetic mutism.
Inherited CJD is caused by the inheritance of a PRNP gene with a mutations
encoding most commonly lysine instead of glutamic acid at position 200 (E200K), and
asparagines instead of aspartic acid at position 178 (D178N) especially when it is
associated with polymorphism in both PRNP genes that encodes valine at position 129
(MM). 10–15% of the cases of CJD are inherited as an autosomal dominant.
About 1% of CJD cases are due to acquired infection. Iatrogenic CJD is
characterized by progressive cerebellar syndrome and behavioral disturbance or
classical CJD syndrome. It attacks people in different age also young. Most cases are
caused by injection of pituitary growth hormone or by implantation of dura mater.
Direct incubation time depends on the site of prion inoculation. 60
Variant CJD is referred to as human BSE, because both disorders are caused by
the same prion. This disease was first reported in 1996 in 10 patients. Compared to the
classical CJD this variant shows atypical clinical manifestation and slower course. Unlike
in CJD, dementia is not the most prominent sign of disease. The early clinical feature
include: depression, anxiety, peripheral sensory symptoms, behavioral change, social
withdrawal, and in later stage: cerebellar ataxia, chorea, or athetosis. vCJD develops in
younger people-age 29; however age at onset 12-74 years is seen. The main cause is 129
MM mutation in PRNP gene.
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There is pericellular PrP deposition in cerebral and

cerebellar cortex. vCJD plaques are also seen in tonsil and other lymphoreticular tissue.
29

Historical connection and many experiments strongly indicate a correlation
between the prion strain that causes vCJD and BSE. The glycosylation pattern in mice
with vCJD was very similar to the pattern found when the transmission of the BSE prion
strain was examined. Lesion profile found in the brain of the mice was identical when an
animal was inoculated with BSE or vCJD agent and distinct from all other not BSE related
TSE’s. The examination of incubation time and survival ratio had the same result. 61
7.5.2. Kuru

Kuru is an invariably fatal disease that appeared at the beginning of 20th Century
among a population living in the Eastern Highlands of Papua New Guinea. Kuru means
“laughing death” and was used by Fore people to describe uncontrollable laughter
accompanied with this disease. Kuru was transmitted among the members of this group
by ritual cannibalism. The disease spread between members of the Fore tribe especially
women and children, because they predominantly participated in the feast and ate
brain and internal organs of their dead relatives. The principal route of kuru
transmission was dietary exposure. The infection could also been transmitted by
inoculation with brain or other tissue via cuts, sores or following eye rubbing into the
conjunctiva. Intracerebral or optic inoculation of experimental animals manifest
clinically as classical CJD, with a rapidly progressive dementia. Peripheral inoculation
leads to progressive cerebellar ataxia. 56
The mean incubation period of kuru have been estimated to be approximately
12 years but sometimes can exceed 50 years. The mean clinical duration of illness is 12
30

months, with a range of 3 months to one year after the appearance of symptoms. The
course tends to be shorter in children. The prion accumulates mainly in cerebellum. The
disease affects both mental and motor function. The central clinical feature is
progressive cerebellar ataxia. The symptoms include: muscle tremors, incoordination of
movement, inability to hold things, involuntary oscillation of the eyes, difficulty in
articulating words, swallowing and finally dementia and death. 54, 56, 61
No new cases of kuru have been reported since 1950’s when disease reached its peak
killing several thousand people. Therefore, it is generally believed that kuru is now
extinct.
7.5.3. Fatal familial insomnia (FFI)

This hereditary prion disease was first reported in Italy, in 1986. It is very rare
disorder that attacks 1 person per 50 million/year between the ages of 40 and 60 years.
The mean duration is approximately 7 to 33 months. Prions affect mainly thalamus in
the brain that results in insomnia. The core clinical features include: disruption of the
normal sleep-wake cycle, insomnia and sympathetic overactivity. Patients exhibits
illusion, hallucinations, poor memory, restlessness, inability to concentrate. Other
symptoms include different motor disturbances, hormonal disturbances especially
growth hormone, increased heart rate and depression. The cause of FFI is associated
with mutation at codon 178 with asparagine instead of aspartic acid (D178N) combined
with methionine homozygosity at codon 129. Heterozygous for methionine at codon
129 patients have a longer survival than homozygous. 54, 61

31

7.5.4. Gerstman-Straussler-Scheinker disease (GSS)

This inherited disease was discovered in 1928 in Germany. It is a very rare
autosomal dominant disorder that attacks 1-10 individuals per 100 million/year. It is
frequently observed in patients at the age of 20-30 and sometimes older. The mean
duration is approximately 10 years. The typical clinical features of this disorder are
slowly progressive cerebellar ataxia with pyramidal features, beginning in the fifth or
sixth decade. Dementia occurs later in a more prolonged course than in CJD. The
symptoms include: incoordination of movement, stumbling, dysarthria, difficulties
swallowing and speaking, amnesia and finally dementia. In contrast to other inherited
prion diseases, it has unique neuropathologic features that consist of widespread,
multicentric PrP–amyloid plaques rather than spongiform changes.

61

They are located

mainly in cerebellum what results in problems to coordinate body movements and
difficulties walking. GSS is associated with several different PRNP mutations. The
patients have inherited at least one copy of a mutated PRNP gene. Some of the most
common mutations are: a change in codon 102 converting proline to leucine (P102L) a
change from alanine at position 117 to valine (A117V). The disease is accompanied with
homozygosity for a polymorphism at position 129 (MM). 55
7.5.5. Alpers’ disease

Alpers’ disease is an extremely rare, fatal prion disease of infants that was first
time described in 1930’s. This chronic encephalopathy is associated with diffuse
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progressive degeneration in the brain cortex. In addition, this disease is characterized by
degeneration and fibrosis of the liver. The clinical features include: motor disturbances,
partial paralysis, seizures, growth retardation, mental disorders, dementia or early
death. 54, 61
7.6. Animal prion disease

Animal prion disease includes: scrapie in sheep, goats, mouflons, transmissible
encephalopathy (TME) in mink, bovine spongiform encephalopathy (BSE) in antelopes,
and cows, feline spongiform encephalopathy (FSE) in domestic cats, exotic ungulate
encephalopathy (EUC) in nyala and greater kudu, and chronic wasting disease (CWD) of
mule deer and elk. Small animals, like mice, hamsters or bank voles can be infected
experimentally. 5
7.6.1. Scrapie

Scrapie is an example of prototype prion disease that affects sheep and goats.
Scrapie has been recognized in Europe for over 200 years and is present in many
countries worldwide. The disease was called ‘scrapie’ based on the characteristic
behavior of the sheep. The mean incubation period range from 2 to 5 years. The clinical
features of the disease include severe weight loss, incoordination of movement due to
loss of motor control, paralysis, dementia, wasting and death.

54

The disease mainly

affects brain of the animal leading to the formation and accumulation of plaques,
vacuoles and amyloid protein deposits. The mode of natural transmission remains still
33

unclear. It can be transmitted from animal to animal in feed that is contaminated with
infected nerve tissue. It can also be transmitted by injection of brain tissue. 54.61

7.6.2. Transmissible mink encephalopathy (TME)

This disease was first reported in 1947 in the United States, when it killed
thousands of minks. It affects both female and male minks usually more than one year
old. The mean incubation period is 7 months. The animals die within a week or
sometimes a month after the appearance of symptoms. The most important clinical
features of the disease are behavioral changes.

61

The animals are increasingly nervous,

aggressive, experience difficulty in eating and they show incoordination of movement.
In the later stage of the disease minks become sleepy, inactive, unresponsive and isolate
themselves. The main cause is dietary exposure for example eating contaminated tissue
such as meat of scrapie-infected sheep. It has been suggested that disease can be
transmitted between foxes through biting. Cattle can be also a source of infection.
Experimentally, TME is produced by intracerebral injection of brain material from
infected sheep or dietary exposure. 55
7.6.3. Bovine spongiform encephalopathy (BSE)

Mad cow disease first time described in 1987 in British cows has caused the
deaths of almost 200000 cattle. Its origin appears to have been cattle feed that
contained brain tissue from sheep infected with scrapie. The mean incubation period is
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4-5 years.
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The first symptoms are behavioral changes such as aggressiveness,

irritability, excessive response to different stimuli like light and sound. The clinical
features comprised incoordination of movement, running and jumping in air, high steps,
paddling and stumbling. In the last stadium of the disease animals have breathing
problems, difficulty in urination and defecation. Animal dies within 1-6 months after the
appearance of symptoms. 54, 61
7.6.4. Feline spongiform encephalopathy (FSE)

This disease was first described in 1990 in a domestic cat in Bristol. It primarily
affects domestic animals and different strains of wild cats. It can be also transmitted to
mice. The disease is characterized by sleepiness, failure to respond to light stimuli,
papillary dilatation, crawling, muscle tremors. 54, 55, 61
7.6.5. Exotic ungulate encephalopathy (EUC)

This disease affects wild ungulates, antilopes, nyalas, gemsboks, oryxs, and
greater kudus. It was first time reported in the nyala in 1987. The morphological analysis
of the brain of infected animals shows typical spongiform changes. The clinical features
include: muscle tremors, incoordination of movement, loss of weight, excessive
salivation, licking of lips. 61
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7.6.6. Chronic wasting disease (CWD)

CWD is a rare disease that affects elk, mule deer, black and white-tailed deer. It
was first time reported in Rocky Mountain elk and the mule deer in 1967. The clinical
features include behavioral changes and progressive loss of condition. 54, 61

7.7. Therapeutic strategies

All recognized prion diseases are invariably fatal and to date no effective therapy is
available. However, the major advances in molecular genetics and in understanding
molecular pathogenesis of prion diseases enable preparing effective therapeutics for
human and animal prion disease. The general purpose of treatment is to slow
progression of the disease not to cure, because of serious damage of the brain that
occurs before clinical symptoms.
The main therapeutic strategies are aimed at reducing the expression level of normal
protein (down regulation of PrP transcription or translation), and prevent conversion of
PrPC (PrPC stabilization by binding it with small ligand) to pathological isoform which in
turn will attenuate prion replication and prolong survival time. (Figure 7)
To date, several drugs which decrease concentration of PrP Sc and target PrPSc
formation have been described in prion infected cell lines. However, none of them is
effective when given around the time of the clinical phase manifestation. The most
effective and least toxic drugs include PPS, porphiryns, amphotericin B, and copper. 62
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Researchers develop active vaccines that markedly delay and prevent brain
disease in mice similar to BSE. One of the latest examples is a mucosal prion vaccine
composed of attenuated Salmonella strain which express prion protein. Vaccines could
prevent animals from becoming infected but their use in humans in order to resist prion
infection needs further research.63
The

most

important

and

promising

progress

has

been

made

in

immunotherapeutic strategies. The latest discovery is antibodies that bind to pathologic
isoform of PrPC and reduce or inhibit its propagation. By binding with PrPSc it enable the
host immune system to recognize the abnormal prion as an invader and attack them.
Transgenic mice expressing antibody against the Tyr-Tyr-Arg amino acid sequence of
PrPSc are protected against peripheral prion infection. Moreover, PrP Sc levels in the
spleen of peripherally infected mice were significantly reduced even when antibody
where administered during the very high level of infectious isoform. 64
For both humans and animal using immunotherapeutic strategies could
significantly inhibit prion propagation, delay the development of prion diseases, and
provide useful screening and diagnostic tool for prion protein.
Recent experiments suggest the role and future importance of RNA interference
in treatment of prion diseases. shRNA against PrPC reduce it expression and decrease its
conversion to pathological isoform. These anti-PrPC shRNA carried on a lentivector is
transcribed in neuronal cell and then processed to form siRNA. siRNA lead to
degradation of mRNA by activation of RNA-induced silencing complex. Transgenic mice
transfected with anti-PrPC sHRNA showed significant increase in survival time. 65
37

Figure 7. Strategies for treatment of prion diseases. 66
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CHAPTER VIII
CONCLUSION
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases
of human, animal and yeast caused by an infectious agent designated prion. The
"protein only" hypothesis proposed more than three decades ago suggests that the
prions are small, infectious pathogens composed of aggregated, abnormal forms of a
protein encoded in the host genome. PrPC plays primary role in neurite outgrowth,
synaptic function, oxidative stress defense and long term survival of cerebellar neurons.
The key event in prion disease is the conversion of the α-helical, cellular isoform of the
prion protein to the insoluble, β-sheet-rich disease- causing isoform. Aggregation of
misfolded prion protein into large amyloid plaques and fibrous structures is associated
with neurodegeneration. TSEs attack the central nervous system leading to progressive
spongiform degeneration of brain tissue. Molecular and cellular pathways leading to
neurodegeneration remains still unclear. However, the recent studies suggest that
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pathway leading to neuronal loss include ubiquitin-proteosome and endosomal system,
oxidative stress, regulated activation of complement, synaptic alterations and dendritic
atrophy.2The study of the unusual properties of the infectious agent and pathology of
neurodegenerative disorders has been a source of excitement and arguments between
the scientists. The major advances in molecular genetics and recent understanding of
prion propagation and neurotoxicity allowed deep insight into prion biology. However,
many aspects of prion disease still raise controversies and questions for a broad
audience of researchers. Understanding the physiological role of PrP, determination of
pathological mechanism of neurodegeneration in prion diseases, explaining the
relationship between TSEs and other neurodegenerative diseases is a big challenge for
the biologist for the next years that will provide the basic for the development of
therapeutic modalities.
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